An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety
<p>This review synthesizes the current evidence to assess the efficacy and safety of caplacizumab in the treatment of iTTP, focusing on its impact on TPE requirements, time to platelet normalization, relapse prevention, and treatment-related adverse events. Thirteen studies (11 observational a...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2025
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513508256776192 |
|---|---|
| author | Mohamed Yassin (4166515) |
| author2 | Rola Ghasoub (16555851) Neda Jafari (22963048) Lulwah Al-Tourah (22963051) Anas Babiker (22963054) Muna AlRasheed (22963057) |
| author2_role | author author author author author |
| author_facet | Mohamed Yassin (4166515) Rola Ghasoub (16555851) Neda Jafari (22963048) Lulwah Al-Tourah (22963051) Anas Babiker (22963054) Muna AlRasheed (22963057) |
| author_role | author |
| dc.creator.none.fl_str_mv | Mohamed Yassin (4166515) Rola Ghasoub (16555851) Neda Jafari (22963048) Lulwah Al-Tourah (22963051) Anas Babiker (22963054) Muna AlRasheed (22963057) |
| dc.date.none.fl_str_mv | 2025-12-20T09:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.blre.2025.101359 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/An_updated_systematic_review_and_meta-analysis_of_Caplacizumab_for_immune_thrombotic_thrombocytopenic_purpura_Insights_into_efficacy_and_safety/31017343 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Caplacizumab Immune thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura Therapeutic plasma exchange iTTP |
| dc.title.none.fl_str_mv | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>This review synthesizes the current evidence to assess the efficacy and safety of caplacizumab in the treatment of iTTP, focusing on its impact on TPE requirements, time to platelet normalization, relapse prevention, and treatment-related adverse events. Thirteen studies (11 observational and 2 RCTs), involving 2956 patients with iTTP were included. The majority of included studies were of high methodological quality, indicating a low risk of bias based on the assessment tools. The analysis found that caplacizumab was associated with significant clinical benefits. It marked a reduction in daily TPE sessions (MD = −3.92, p < 0.001) and time to platelet normalization (MD = −2.44, p = 0.03). Caplacizumab also significantly reduced mortality (RR = 0.29, p < 0.001) and iTTP exacerbations (RR = 0.27, p < 0.001), leading to shorter hospital stays (MD = −5.13, p = 0.001). Caplacizumab demonstrated notable clinical benefits in managing iTTP, with significant reductions in daily TPE sessions, time to platelet normalization, mortality, and iTTP exacerbations. Promising results were also noticed for early initiation compared to delayed initiation.</p><h2>Other Information</h2> <p> Published in: Blood Reviews<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.blre.2025.101359" target="_blank">https://dx.doi.org/10.1016/j.blre.2025.101359</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_43803a1867b07ef562c47410b247eb98 |
| identifier_str_mv | 10.1016/j.blre.2025.101359 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/31017343 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safetyMohamed Yassin (4166515)Rola Ghasoub (16555851)Neda Jafari (22963048)Lulwah Al-Tourah (22963051)Anas Babiker (22963054)Muna AlRasheed (22963057)Biomedical and clinical sciencesCardiovascular medicine and haematologyPharmacology and pharmaceutical sciencesCaplacizumabImmune thrombotic thrombocytopenic purpuraThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeiTTP<p>This review synthesizes the current evidence to assess the efficacy and safety of caplacizumab in the treatment of iTTP, focusing on its impact on TPE requirements, time to platelet normalization, relapse prevention, and treatment-related adverse events. Thirteen studies (11 observational and 2 RCTs), involving 2956 patients with iTTP were included. The majority of included studies were of high methodological quality, indicating a low risk of bias based on the assessment tools. The analysis found that caplacizumab was associated with significant clinical benefits. It marked a reduction in daily TPE sessions (MD = −3.92, p < 0.001) and time to platelet normalization (MD = −2.44, p = 0.03). Caplacizumab also significantly reduced mortality (RR = 0.29, p < 0.001) and iTTP exacerbations (RR = 0.27, p < 0.001), leading to shorter hospital stays (MD = −5.13, p = 0.001). Caplacizumab demonstrated notable clinical benefits in managing iTTP, with significant reductions in daily TPE sessions, time to platelet normalization, mortality, and iTTP exacerbations. Promising results were also noticed for early initiation compared to delayed initiation.</p><h2>Other Information</h2> <p> Published in: Blood Reviews<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.blre.2025.101359" target="_blank">https://dx.doi.org/10.1016/j.blre.2025.101359</a></p>2025-12-20T09:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.blre.2025.101359https://figshare.com/articles/journal_contribution/An_updated_systematic_review_and_meta-analysis_of_Caplacizumab_for_immune_thrombotic_thrombocytopenic_purpura_Insights_into_efficacy_and_safety/31017343CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/310173432025-12-20T09:00:00Z |
| spellingShingle | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety Mohamed Yassin (4166515) Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Caplacizumab Immune thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura Therapeutic plasma exchange iTTP |
| status_str | publishedVersion |
| title | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| title_full | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| title_fullStr | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| title_full_unstemmed | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| title_short | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| title_sort | An updated systematic review and meta-analysis of Caplacizumab for immune thrombotic thrombocytopenic purpura: Insights into efficacy and safety |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Pharmacology and pharmaceutical sciences Caplacizumab Immune thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura Therapeutic plasma exchange iTTP |